Literature DB >> 19131665

Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone.

Tarek Z Deeb1, Douglas Sharp, Tim G Hales.   

Abstract

Homomeric 5-hydroxytryptamine (5-HT)(3A) and heteromeric 5-HT(3AB) receptors mediate rapid excitatory responses to serotonin in the central and peripheral nervous systems. The alkaloid morphine, in addition to being a mu-opioid receptor agonist, is a potent competitive inhibitor of 5-HT(3) receptors. We examined whether methadone, an opioid often used to treat morphine dependence, also exhibited 5-HT(3) receptor antagonist properties. Racemic (R/S)-methadone inhibited currents mediated by human homomeric 5-HT(3A) receptors (IC(50) = 14.1 +/- 2.5 microM). Incorporation of the 5-HT(3B) subunit into heteromeric 5-HT(3AB) receptors reduced the potency of inhibition by (R/S)-methadone (IC(50) = 41.1 +/- 0.9 microM). (R/S)-Methadone also increased apparent desensitization of both 5-HT(3) receptor subtypes. The inhibition of the 5-HT(3A) receptor was competitive; however, incorporation of the 5-HT(3B) subunit caused the appearance of inhibition that was insurmountable by 5-HT. In the absence of rapid desensitization, when dopamine was used as an agonist of 5-HT(3AB) receptors, the inhibition by (R/S)-methadone was voltage-dependent. The antagonist and desensitization-enhancing effects of (R/S)-methadone were shared by pure (R)- and (S)-methadone enantiomers, which had similar actions on 5-HT-evoked currents mediated by 5-HT(3) receptors. However, (R)-methadone exhibited a larger voltage-dependent inhibition of dopamine-evoked currents mediated by 5-HT(3AB) receptors than did (S)-methadone. Inhibition of 5-HT(3A) receptors by (R/S)-methadone was not influenced by voltage. Thus, methadone displays multimodal subunit-dependent antagonism of 5-HT(3) receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131665      PMCID: PMC2684931          DOI: 10.1124/mol.108.053322

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit.

Authors:  A E Dubin; R Huvar; M R D'Andrea; J Pyati; J Y Zhu; K C Joy; S J Wilson; J E Galindo; C A Glass; L Luo; M R Jackson; T W Lovenberg; M G Erlander
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

2.  Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine.

Authors:  Mladen Vassilev Tzvetkov; Cornelia Meineke; Elke Oetjen; Karen Hirsch-Ernst; Jürgen Brockmöller
Journal:  Gene       Date:  2006-08-23       Impact factor: 3.688

3.  The effects of morphine on human 5-HT3A receptors.

Authors:  Maria Wittmann; I Peters; T Schaaf; H C Wartenberg; S Wirz; J Nadstawek; B W Urban; M Barann
Journal:  Anesth Analg       Date:  2006-09       Impact factor: 5.108

4.  Methadone increases intracellular calcium in SH-SY5Y and SH-EP1-halpha7 cells by activating neuronal nicotinic acetylcholine receptors.

Authors:  Jukka S Pakkanen; Heli Nousiainen; Jari Yli-Kauhaluoma; Irene Kylänlahti; Tommi Möykkynen; Esa R Korpi; Jian-Hong Peng; Ronald J Lukas; Liisa Ahtee; Raimo K Tuominen
Journal:  J Neurochem       Date:  2005-07-05       Impact factor: 5.372

Review 5.  Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor.

Authors:  John A Peters; Tim G Hales; Jeremy J Lambert
Journal:  Trends Pharmacol Sci       Date:  2005-09-27       Impact factor: 14.819

6.  Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.

Authors:  C B Eap; S Crettol; J-S Rougier; J Schläpfer; L Sintra Grilo; J-J Déglon; J Besson; M Croquette-Krokar; P-A Carrupt; H Abriel
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

Review 7.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

8.  Two kinds of tryptamine receptor.

Authors:  J H GADDUM; Z P PICARELLI
Journal:  Br J Pharmacol Chemother       Date:  1957-09

9.  The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor.

Authors:  Xiang-Qun Hu; Robert W Peoples
Journal:  J Biol Chem       Date:  2008-01-10       Impact factor: 5.157

10.  Detection of human and rodent 5-HT3B receptor subunits by anti-peptide polyclonal antibodies.

Authors:  David C Reeves; Sarah C R Lummis
Journal:  BMC Neurosci       Date:  2006-03-29       Impact factor: 3.288

View more
  6 in total

Review 1.  Allosteric modulation of the 5-HT(3) receptor.

Authors:  Paul A Davies
Journal:  Curr Opin Pharmacol       Date:  2011-02-20       Impact factor: 5.547

2.  The 5-HT3B subunit affects high-potency inhibition of 5-HT3 receptors by morphine.

Authors:  Daniel T Baptista-Hon; Tarek Z Deeb; Nidaa A Othman; Douglas Sharp; Tim G Hales
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site.

Authors:  Andrew J Thompson; Gavin E Jarvis; Rujee K Duke; Graham A R Johnston; Sarah C R Lummis
Journal:  Neuropharmacology       Date:  2010-11-05       Impact factor: 5.250

Review 4.  Discriminating between 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.

Authors:  Shiow-Ling Wu; Sheng-Chang Wang; Hsiao-Hui Tsou; Hsiang-Wei Kuo; Ing-Kang Ho; Sheng-Wen Liu; Ya-Ting Hsu; Yao-Sheng Chang; Yu-Li Liu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

6.  The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.